86 / 89
86
bortezomib
plus
melphalan-prednisone
versus
melphalan-prednisone. Blood 2010;116:3743-50.
63.
Delforge M, Terpos E, Richardson PG, Shpilberg O,
Khuageva NK, Schlag R, et al. Fewer bone disease events,
improvement in bone remodeling, and evidence of bone
healing with bortezomib plus melphalan-prednisone vs.
melphalan-prednisone in the phase III VISTA trial in
multiple myeloma. 1. Eur J Haematol 2011;86:372-84.
64.
Delforge M, Dhawan R, Robinson D Jr, Meunier J,
Regnault A, Esseltine DL, et al. Health-related quality of
life in elderly, newly diagnosed multiple myeloma
patients treated with VMP vs. MP: results from the VISTA
trial. Eur J Haematol 2012;89:16-27.
65.
Maiolino A, Hungria VT, Garnica M, Oliveira-Duarte G,
Oliveira LC, Mercante DR, et al. Thalidomide plus
dexamethasone as a maintenance therapy after
autologous hematopoietic stem cell transplantation
improves progression-free survival in multiple myeloma.
Am J Hematol 2012;87:948-52.
66.
Weber DM, Chen C, Niesvizky R, Wang M, Belch A,
Stadtmauer EA, et al. Lenalidomide plus dexamethasone
for relapsed multiple myeloma in North America. N Engl
J Med 2007;357:2133-42.
67.
Dimopoulos M, Spencer A, Attal M, Prince HM,
Harousseau JL, Dmoszynska A, et al. Lenalidomide plus
dexamethasone for relapsed or refractory multiple
myeloma. N Engl J Med 2007;357:2123-32.
68.
vopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M,
Stadtmauer EA, et al. Long-term follow-up on overall
survival from the MM-009 and MM-010 phase III trials of
lenalidomide plus dexamethasone in patients with
relapsed or refractory multiple myeloma. Leukemia
2009;23:2147-52.